Prognostic Significance of Human Epidermal Receptor (HER)-3 Immunohistochemical Expression in Patients with Metastatic Breast Cancer |
Olmez, Omer Fatih
(Department of Medical Oncology, Uludag University Medical School)
Evrensel, Turkkan (Department of Medical Oncology, Uludag University Medical School) Cubukcu, Erdem (Department of Medical Oncology, Uludag University Medical School) Ugras, Nesrin (Department of Pathology, Uludag University Medical School) Avci, Nilufer (Department of Medical Oncology, Uludag University Medical School) Canhoroz, Mustafa (Department of Medical Oncology, Uludag University Medical School) Deligonul, Adem (Department of Medical Oncology, Uludag University Medical School) Hartavi, Mustafa (Department of Medical Oncology, Uludag University Medical School) Olmez, Fatma (Department of Obstetrics and Gynecology, Sevket Yilmaz Education and Research Hospital) Cubukcu, Sinem (Department of Medical Oncology, Uludag University Medical School) Tolunay, Sahsine (Department of Pathology, Uludag University Medical School) Kurt, Ender (Department of Medical Oncology, Uludag University Medical School) Kanat, Ozkan (Department of Medical Oncology, Uludag University Medical School) Manavoglu, Osman (Department of Medical Oncology, Uludag University Medical School) |
1 | Allred DC (2010). Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol, 23, 52-9. DOI ScienceOn |
2 | Amler LC (2010). HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin Biol Ther, 10, 1343-55. DOI ScienceOn |
3 | Bieche I, Onody P, Tozlu S, et al (2003). Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer, 106, 758-65. DOI ScienceOn |
4 | Bloom HJ, Richardson WW (1957). Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer, 11, 359-77. DOI ScienceOn |
5 | Brufsky A (2010). Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol, 33, 186-95. |
6 | Arslan C, Altundag K, Dizdar O (2011). Emerging drugs in metastatic breast cancer: an update. Expert Opin Emerg Drugs, 16, 647-67. DOI ScienceOn |
7 | Chaudhri RA, Olivares-Navarrete R, Cuenca N, et al (2012). Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-. J Biol Chem, 287, 7169-81. DOI ScienceOn |
8 | Cortazar P, Justice R, Johnson J, et al (2012). US food and drug administration approval overview in metastatic breast cancer. J Clin Oncol, 30, 1705-11. DOI |
9 | Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012). Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov, 11, 479-97. DOI ScienceOn |
10 | Goel S, Chirgwin J, Francis P, et al (2011). Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research. Breast, 20, 101-10. DOI ScienceOn |
11 | Gullick WJ (1996). The c-erbB3/HER3 receptor in human cancer. Cancer Surv, 27, 339-49. |
12 | Keating GM (2012). Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs, 72, 353-60. DOI ScienceOn |
13 | Koutras AK, Kalogeras KT, Dimopoulos MA, et al (2008). Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer. Br J Cancer, 99, 1775-85. DOI ScienceOn |
14 | Koutras AK, Fountzilas G, Kalogeras KT, et al (2010). The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol, 74, 73-8. DOI ScienceOn |
15 | Lee Y, Cho S, Seo JH, et al (2007). Correlated expression of erbB-3 with hormone receptor expression and favourable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol, 128, 1041-9. DOI ScienceOn |
16 | Liu Y, Liu Q, Wang T, et al (2013). Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer, 13, 202. DOI ScienceOn |
17 | Lorusso P, Janne PA, Oliveira M, et al (2013). Phase I Study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res, 19, 3078-87 DOI ScienceOn |
18 | Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S (2005). Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat, 90, 65-70. DOI |
19 | Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA (2012). Making genuine progress against metastatic breast cancer. J Clin Oncol, 30, 3448-51. DOI ScienceOn |
20 | Michaelson JS, Silverstein M, Sgroi D, et al (2003). The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer, 98, 2133-43. DOI ScienceOn |
21 | Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP (2000). Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription polymerase chain reaction assay. Clin Cancer Res, 6, 4217-25. |
22 | Nanda R (2007). Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials, 2, 111-6. DOI |
23 | Ocana A, Vera-Badillo F, Seruga B, et al (2013). HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst, 105, 266-73. DOI |
24 | Orphanos G, Kountourakis P (2012). Targeting the HER2 receptor in metastatic breast cancer. Hematol Oncol Stem Cell Ther, 5, 127-37. DOI ScienceOn |
25 | Ravdin PM, Green S, Dorr TM, et al (1992). Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest oncology group study. J Clin Oncol, 10, 1284-91. |
26 | Sassen A, Rochon J, Wild P, et al (2008). Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res, 10, 2. |
27 | Stern DF (2008). ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia, 13, 215-23. DOI |
28 | Sumida T, Itahana Y, Hamakawa H, Desprez PY (2004). Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins. Cancer Res, 64, 7886-92. DOI ScienceOn |
29 | Tafe LJ, Tsongalis GJ (2011). The human epidermal growth factor receptor 2 (HER2). Clin Chem Lab Med, 50, 23-30. |
30 | Tanner B, Hasenclever D, Stern K, et al (2006). ErB-3 predicts survival in ovarian cancer. J Clin Oncol, 24, 4317-23. DOI ScienceOn |
31 | Vaught DB, Stanford JC, Young C, et al (2012). HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res, 72, 2672-82. DOI |
32 | Way TD, Lin JK (2005). Role of HER2/HER3 co-receptor in breast carcinogenesis. Future Oncol, 1, 841-9. DOI |
33 | Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 200, 290-7. DOI ScienceOn |